Red blood cells serve as intravascular carriers of myeloperoxidase

Journal of Molecular and Cellular Cardiology

Volumn 74, Issue , 2014, Pages 353-363

  Adam, Matti ^a   Gajdova, Silvie ^b   Kolarova, Hana ^b   Kubala, Lukas ^b,c   Lau, Denise ^d   Geisler, Anne ^d   Ravekes, Thorben ^e   Rudolph, Volker ^e   Tsao, Philip S ^a   Blankenberg, Stefan ^d   Baldus, Stephan ^e   Klinke, Anna ^e  

^a STANFORD UNIVERSITY   (United States)

^b INSTITUTE OF BIOPHYSICS   (Czech Republic)

^c ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^d UNIVERSITY OF HAMBURG   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Cell membranes; Erythrocyte; Myeloperoxidase; Systemic vascular resistance; Vascular endothelium dependent relaxation

Indexed keywords

MYELOPEROXIDASE; NITRIC OXIDE; HEPARIN; PEROXIDASE; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME RELEASE; ERYTHROCYTE; HEART LEFT VENTRICLE PRESSURE; HEART LEFT VENTRICLE VOLUME; HEART OUTPUT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN TRANSPORT; SYSTEMIC VASCULAR RESISTANCE; VASCULAR RING; VASODILATATION; ACUTE CORONARY SYNDROME; ANIMAL; AORTA; BLOOD; C57BL MOUSE; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; HEART; HEART FAILURE; METABOLISM; ORGAN CULTURE TECHNIQUE; PATHOLOGY; TISSUE CULTURE TECHNIQUE; TRANSPORT AT THE CELLULAR LEVEL; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE;

ACUTE CORONARY SYNDROME; ANIMALS; AORTA; BIOLOGICAL TRANSPORT; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; ERYTHROCYTES; HEART; HEART FAILURE; HEPARIN; HUMANS; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE; ORGAN CULTURE TECHNIQUES; PEROXIDASE; PROTEIN BINDING; TISSUE CULTURE TECHNIQUES; VASCULAR RESISTANCE;

EID: 84904748387     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.06.009     Document Type: Article

References (37)

1. Klebanoff S.J. Myeloperoxidase: friend and foe. J Leukoc Biol 2005, 77:598-625.
2. Klebanoff S.J. Myeloperoxidase: contribution to the microbicidal activity of intact leukocytes. Science 1970, 169:1095-1097.
3. van der Veen B.S., de Winther M.P., Heeringa P. Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease. Antioxid Redox Signal 2009, 11:2899-2937.
4. Klinke A., Nussbaum C., Kubala L., Friedrichs K., Rudolph T.K., Rudolph V., et al. Myeloperoxidase attracts neutrophils by physical forces. Blood 2011, 117:1350-1358.
5. Marilyn J.T. Erythrocyte adhesion receptors: blood group antigens and related molecules. Transfus Med Rev 2005, 19:32-44.
6. Eiserich J.P., Baldus S., Brennan M.-L., Ma W., Zhang C., Tousson A., et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002, 296:2391-2394.
7. Rudolph T.K., Wipper S., Reiter B., Rudolph V., Coym A., Detter C., et al. Myeloperoxidase deficiency preserves vasomotor function in humans. Eur Heart J 2012, 33(13):1625-1634.
8. Pacher P., Nagayama T., Mukhopadhyay P., Batkai S., Kass D.A. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc. 2008, 3:1422-1434.
9. Baldus S., Rudolph V., Roiss M., Ito W.D., Rudolph T.K., Eiserich J.P., et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation 2006, 113:1871-1878.
10. Nussbaum C., Klinke A., Adam M., Baldus S., Sperandio M. Myeloperoxidase-a leukocyte-derived protagonist of inflammation and cardiovascular disease. Antioxid Redox Signal 2013, 18(6):692-713.
11. Reeves E.P., Nagl M., Godovac-Zimmermann J., Segal A.W. Reassessment of the microbicidal activity of reactive oxygen species and hypochlorous acid with reference to the phagocytic vacuole of the neutrophil granulocyte. J Med Microbiol 2003, 52:643-651.
12. Suzuki M., Asako H., Kubes P., Jennings S., Grisham M.B., Granger D.N. Neutrophil-derived oxidants promote leukocyte adherence in postcapillary venules. Microvasc Res 1991, 42:125-138.
13. Lefkowitz D.L., Mills K., Morgan D., Lefkowitz S.S. Macrophage activation and immunomodulation by myeloperoxidase. Proc Soc Exp Biol Med 1992, 199:204-210.
14. Johnson R.J., Guggenheim S.J., Klebanoff S.J., Ochi R.F., Wass A., Baker P., et al. Morphologic correlates of glomerular oxidant injury induced by the myeloperoxidase-hydrogen peroxide-halide system of the neutrophil. Lab Invest 1988, 58:294-301.
15. Wang J.-G., Mahmud S.A., Nguyen J., Slungaard A. Thiocyanate-dependent induction of endothelial cell adhesion molecule expression by phagocyte peroxidases: a novel HOSCN-specific oxidant mechanism to amplify inflammation. J Immunol 2006, 177:8714-8722.
16. van Oss C.J., Absolom D.R. Zeta potentials, van der Waals forces and hemagglutination. Vox Sang 1983, 44:183-190.
17. Telen M.J. Erythrocyte adhesion receptors: blood group antigens and related molecules. Transfus Med Rev 2005, 19:32-44.
18. de Oliveira S., Saldanha C. An overview about erythrocyte membrane. Clin Hemorheol Microcirc 2010, 44:63-74.
19. Forghani R., Wojtkiewicz G.R., Zhang Y., Seeburg D., Bautz B.R., Pulli B., et al. Demyelinating diseases: myeloperoxidase as an imaging biomarker and therapeutic target. Radiology 2012, 263:451-460.
20. Sharif R., Dawra R., Wasiluk K., Phillips P., Dudeja V., Kurt-Jones E., et al. Impact of toll-like receptor 4 on the severity of acute pancreatitis and pancreatitis-associated lung injury in mice. Gut 2009, 58:813-819.
21. Queiroz-Junior C.M., Pacheco C.M., Fonseca A.H., Klein A., Caliari M.V., de Francischi J.N. Myeloperoxidase content is a marker of systemic inflammation in a chronic condition: the example given by the periodontal disease in rats. Mediat Inflamm 2009, 2009:760837.
22. Rudolph V., Andrie R.P., Rudolph T.K., Friedrichs K., Klinke A., Hirsch-Hoffmann B., et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med 2010, 16:470-474.
23. Askari A.T., Brennan M.L., Zhou X., Drinko J., Morehead A., Thomas J.D., et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med 2003, 197:615-624.
24. Buffon A., Biasucci L.M., Liuzzo G., D'Onofrio G., Crea F., Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002, 347:5-12.
25. Rudolph V., Steven D., Gehling U.M., Goldmann B., Rudolph T.K., Friedrichs K., et al. Coronary plaque injury triggers neutrophil activation in patients with coronary artery disease. Free Radic Biol Med 2007, 42:460-465.
26. Cotter G., Metra M., Milo-Cotter O., Dittrich H.C., Gheorghiade M. Fluid overload in acute heart failure-re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 2008, 10:165-169.
27. Holzhauser L., Zolty R. Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening. Heart Fail Rev 2014, 1-16.
28. Rubattu S., Calvieri C., Pagliaro B., Volpe M. Atrial natriuretic peptide and regulation of vascular function in hypertension and heart failure: implications for novel therapeutic strategies. J Hypertens 2013, 31:1061-1072.
29. Brennan M.L., Penn M.S., Van Lente F., Nambi V., Shishehbor M.H., Aviles R.J., et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003, 349:1595-1604.
30. Heslop C.L., Frohlich J.J., Hill J.S. Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography. J Am Coll Cardiol 2010, 55:1102-1109.
31. Khan S.Q., Kelly D., Quinn P., Davies J.E., Ng L.L. Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction. Heart 2007, 93:826-831.
32. Meuwese M.C., Stroes E.S., Hazen S.L., van Miert J.N., Kuivenhoven J.A., Schaub R.G., et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007, 50:159-165.
33. Rudolph V., Rudolph T.K., Hennings J.C., Blankenberg S., Schnabel R., Steven D., et al. Activation of polymorphonuclear neutrophils in patients with impaired left ventricular function. Free Radic Biol Med 2007, 43:1189-1196.
34. Tang W.H., Brennan M.L., Philip K., Tong W., Mann S., Van Lente F., et al. Plasma myeloperoxidase levels in patients with chronic heart failure. Am J Cardiol 2006, 98:796-799.
35. Yunoki K., Naruko T., Sugioka K., Inaba M., Iwasa Y., Komatsu R., et al. Erythrocyte-rich thrombus aspirated from patients with ST-elevation myocardial infarction: association with oxidative stress and its impact on myocardial reperfusion. Eur Heart J 2012, 33:1480-1490.
36. Baldus S., Heeschen C., Meinertz T., Zeiher A.M., Eiserich J.P., Munzel T., et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003, 108:1440-1445.
37. Lau D., Baldus S. Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharmacol Ther 2006, 111:16-26.